VarmX BV, which is developing an anticoagulant rescue agent, has appointed Jan Öhrström as chief executive and Alex Gold to its supervisory board. Dr Öhrström, who has been chairman of the company since 2018, has extensive experience in the development of blood coagulation factors. VarmX’s experimental drug is designed to reverse life-threatening bleeding that can arise from anticoagulant therapy. Dr Gold, the new supervisory board member, is a cardiologist with expertise in the development of new cardiovascular therapies.
VarmX announced the appointments on 15 June 2021.
Copyright 2021 Evernow Publishing Ltd